1. Home
  2. VAL vs ORKA Comparison

VAL vs ORKA Comparison

Compare VAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

HOLD

Current Price

$75.40

Market Cap

5.4B

Sector

Energy

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$87.30

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VAL
ORKA
Founded
1975
2004
Country
Bermuda
United States
Employees
5070
68
Industry
Oil & Gas Production
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VAL
ORKA
Price
$75.40
$87.30
Analyst Decision
Hold
Strong Buy
Analyst Count
5
12
Target Price
$64.00
$92.50
AVG Volume (30 Days)
846.9K
1.3M
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.76
N/A
P/E Ratio
$16.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.23
$10.97
52 Week High
$114.12
$91.00

Technical Indicators

Market Signals
Indicator
VAL
ORKA
Relative Strength Index (RSI) 30.68 73.57
Support Level $47.57 $27.81
Resistance Level $104.05 $91.00
Average True Range (ATR) 3.04 4.74
MACD -1.03 2.27
Stochastic Oscillator 6.09 93.72

Price Performance

Historical Comparison
VAL
ORKA

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Share on Social Networks: